3 February 2012 - Threshold Pharmaceuticals Inc (NASDAQ:THLD) has signed a global agreement with Germany's Merck KGaA (ETR:MRK) for the joint development and commercialisation of TH-302, Threshold's small molecule hypoxia-targeted drug.

Under the terms of the deal, Merck will rece...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up